{"entity":{"id":"immuneoncia-therapeutics","kind":"company","name":"ImmuneOncia Therapeutics","aka":["ImmuneOncia Therapeutics Inc."],"tldr":"ImmuneOncia Therapeutics is a South Korea-based biotechnology company running 2 late-stage cancer trials of IMC-001 in peripheral T-cell lymphomas.","summary":"ImmuneOncia Therapeutics, based in Yongin-si, South Korea, is a biotechnology company. ImmuneOncia Therapeutics develops immuno-oncology antibody drugs, stating its aim is to bring Korea's first immuno-oncology drug to market. On ClinicalTrials.gov it is the lead sponsor of 2 recruiting or active phase 2 and phase 3 interventional cancer trials, testing IMC-001 in peripheral T-cell lymphomas. The largest, NCT06365840 (A Study of IMC-001 In Patients With Metastatic Or Locally Advanced TMB-H Solid Tumour), plans to enrol 30 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.immuneoncia.com"},{"label":"ClinicalTrials.gov: trials led by ImmuneOncia Therapeutics","url":"https://clinicaltrials.gov/search?lead=ImmuneOncia%20Therapeutics%20Inc."}],"tags":["ctgov-sponsor"],"related":[],"cancers":["peripheral-t-cell-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":["nct06365840","nct04414163"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Yongin-si","country":"KR","companyType":"biotech","website":"https://www.immuneoncia.com","investors":[],"funding":[]},"route":"/companies/immuneoncia-therapeutics/","neighbours":{"cancer":[{"id":"peripheral-t-cell-lymphoma","kind":"cancer","name":"Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma)","route":"/cancers/peripheral-t-cell-lymphoma/"}],"term":[{"id":"clinical-trial","kind":"term","name":"Clinical trial","route":"/terms/clinical-trial/"},{"id":"pivotal-trial","kind":"term","name":"Pivotal (registrational) trial","route":"/terms/pivotal-trial/"}],"trial":[{"id":"nct06365840","kind":"trial","name":"A Study of IMC-001 In Patients With Metastatic Or Locally Advanced TMB-H Solid Tumor","route":"/trials/nct06365840/"},{"id":"nct04414163","kind":"trial","name":"A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type","route":"/trials/nct04414163/"}]}}